Synaptic Proteins as Fluid Biomarkers in Alzheimer’s Disease: A Systematic Review and Meta-Analysis
Authors:
- 6 December 2022
- journal article
- review article
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 90 (4) , 1381-1393
Abstract
Background: Synaptic disruption precedes neuronal death and correlates with clinical features of Alzheimer’s disease (AD). The identification of fluid biomarkers of synaptic damage is emerging as a goal for early and accurate diagnosis of the disease. Objective: To perform a systematic review and meta-analysis to determine whether fluid biomarkers of synaptic damage are impaired in AD. Methods: PubMed, Scopus, EMBASE, and Web of Science were searched for articles reporting synaptic proteins as fluid biomarkers in AD and cognitively unimpaired (CU) individuals. Pooled effect sizes were determined using the Hedge G method with random effects. Questions adapted from the Quality Assessment of Diagnostic Accuracy Studies were applied for quality assessment. A protocol for this study has been previously registered in PROSPERO (registration number: CRD42021277487). Results: The search strategy identified 204 articles that were assessed for eligibility. A total of 23 studies were included in the systematic review and 15 were included in the meta-analysis. For Neurogranin, 827 AD and 1,237 CU subjects were included in the meta-analysis, showing a significant increase in cerebrospinal fluid of patients with AD compared to CU individuals, with an effect size of 1.01 (p < 0.001). A significant increase in SNAP-25 and GAP-43 levels in CSF of patients with AD was observed. Conclusion: Neurogranin, SNAP-25, and GAP-43 are possible biomarkers of synaptic damage in AD, and other potential synaptic biomarkers are emerging. This meta-analysis also revealed that there are still relatively few studies investigating these biomarkers in patients with AD or other dementias and showed wide heterogeneity in literature.Keywords
This publication has 49 references indexed in Scilit:
- Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer’s diseaseBrain, 2015
- Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteriaThe Lancet Neurology, 2014
- Alzheimer disease pathology in cognitively healthy elderly: A genome-wide studyNeurobiology of Aging, 2011
- QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy StudiesAnnals of Internal Medicine, 2011
- Factors associated with resistance to dementia despite high Alzheimer disease pathologyNeurology, 2009
- Neurogranin/RC3 Enhances Long-Term Potentiation and Learning by Promoting Calcium-Mediated SignalingThe Journal of Neuroscience, 2004
- Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairmentAnnals of Neurology, 1991
- Demonstration of Amyloid Deposits and Neurofibrillary Changes in Whole Brain SectionsBrain Pathology, 1991
- Amyloid deposition as the central event in the aetiology of Alzheimer's diseaseTrends in Pharmacological Sciences, 1991
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984